Q3 FY22 Earnings Presentation

Table of Executive Portfolio Financial Guidance & Contents Summary Highlights Highlights Assumptions Neuroscience (continued) COVID-19 driven procedural slowdowns; share gains and strong product pipeline Specialty Therapies . Pelvic Health MSD Sequential market decline due to COVID-19 impact on procedural volumes especially in January Expecting approval of InterStim XTM in the first half of 2022 Neurovascular LDD Growth driven by Flow Diverters, and overall strong performance in Emerging Markets Hemorrhagic: Growth driven by strength of Flow Diversion products - Pipeline TM Vantage in OUS and Pipeline TM Shield in the U.S., Pipeline™ Flex with Shield Technology in Japan and the U.S. ENT Ischemic: Closed the first two Viz.Al agreements in Western Europe LSD Decline driven by supply chain disruptions in disposables that are anticipated to improve in Q4 17 Q3 FY22 earnings presentation | February 22, 2022 Verderonic ESG Appendix PipelineTM Vantage Embolization Device with Shield Technology™ InterStim™ Micro System INTERIM 11 NIM Vital™ Neuroscience 51% 30% Specialty Therapies Cranial & Spinal Technologies 19% Neuromodulation Medtronic

View entire presentation